Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GBS-NN/NN2 Vaccine in Pregnant Women
NCT05154578Phase 2Completed
- Sponsor
- MinervaX
- Start
- Feb 2022
- Primary completion
- Apr 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of GBS-NN/NN2 vaccine in group B streptococcal infection (5 arms), sponsored by MinervaX. Primary endpoint: Concentrations of Immunoglobulin (Ig) G Antibodies Specific to the AlpN Proteins in Cord Blood From Each Baby. Started Feb 2022; status: completed.
02
Drugs
GBS-NN/NN2 vaccine
03
Conditions
group B streptococcal infection
Beyond the preview
Go deeper on NCT05154578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05154578.